Rubovszky, G.
National Institute of Oncology
2 papers on CoChatORCID 0000-0003-1723-5589
Most cited papers
- Verified
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
André, F., Ciruelos, E. M., Juric, D., Loibl, S., Campone, M., Mayer, I. A., Rubovszky, G., Yamashita, T., Kaufman, B., Lu, Y.-S., et al. (2021) · Annals of Oncology
Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer
Cited by 624
- Verified
Abstract GS3-08: Alpelisib + fulvestrant for advanced breast cancer: Subgroup analyses from the phase III SOLAR-1 trial
Juric, D., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H., Iwata, H., Conte, P., Mayer, I., Kaufman, B., et al. (2019) · Cancer Research
Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer
Cited by 62
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free